EDIT

Editas Medicine, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-09

Figures on this page computed 2026-11-08 13:00 UTC

Last close

2.72USD

Market data, 2026-11-04

EDIT: weekly closes from 2.47 on 2025-11-07 to 2.72 on 2026-11-04, a move of +10.1%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-04

Over that span: +10.1%

Except where said otherwise: 10-K for 2025, filed 2026-03-09

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-09
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-05
The filing itself
-395.0%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself
-409.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself
2.81Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-05
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.30 against 0.58 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.13x

1.04x

1.35x

1.62x

0.14x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-09

Sales1.13x
Its own average over 10 years, 35.9M.
Profit1.04x
Its own average over 10 years, -154.0M.
Free cash flow1.35x
Its own average over 10 years, -122.5M.
Debt1.62x
Its own average over 7 years, 47.3M.
Price0.14x
Its own average over 11 years, 19. Market data, 2026-11-04

Price is furthest from its own average, at 0.14 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	n/a
2017-12-31	226.8	n/a
2018-12-31	527.6	n/a
2019-12-31	339.2	100.0
2020-12-31	1,499.0	117.3
2021-12-31	422.0	135.3
2022-12-31	325.7	137.4
2023-12-31	1,290.6	152.0
2024-12-31	533.9	164.7
2025-12-31	669.4	177.6

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001650664-26-000017
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001650664-26-000017
Reported in: USD

The filing itself

Figures behind the shape

Growth

-14.9%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate-14.9%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income32.5%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-586.6%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-05
The filing itself
Return on equity-586.6%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-05
The filing itself
Return on assets-85.8%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-05
The filing itself

Margins

-394.9%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself
Operating margin-394.9%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself
Net margin-395.0%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself
Free cash flow margin-409.3%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself

Price

8.4x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-09
The filing itself
Price to book8.4x10-Q for 2025, filed 2026-08-05
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001650664-26-000083
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-05
- computed
- 10-K for 2025, filed 2026-03-09
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-03-09
The filing itself
Price to sales ratio5.6x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself

Safety

2.81

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity2.81
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-05
The filing itself
Current ratio3.5410-Q for 2025, filed 2026-08-05
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001650664-26-000083
Reported in
USD
- 10-Q for 2025, filed 2026-08-05
- 10-Q for 2025, filed 2026-08-05
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself
Altman Z-Score-13.22
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-09
- Computed from the 10-K for 2025, filed 2026-03-09
- Computed from the 10-K for 2025, filed 2026-03-09
- Computed from the 10-K for 2025, filed 2026-03-09
- Computed from the 10-K for 2025, filed 2026-03-09

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001650664-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- Computed from the 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.